Cancer is not a single disease but a collection of heterogenous subtypes. For effective treatment of cancer, it is essential to identify different cancer subtypes and understand their mechanisms. Recent advances of AL and ML offer new ways to analysis and integrate rich data from patients, and it could lead to new insights on cancer mechanisms and novel biomarkers. I will use examples to discuss opportunities and challenges of applying ML and AI for precision oncology
Han Chang is the Director of Head of Late Stage Oncology, Translational Bioinformatics at Bristol-Myers Squibb where he is leading a team of analysts applying cutting-edge bioinformatics, statistics, and machine learning methods. He is working with clinical and large-scale data sets from BMS’s industry-leading late-stage oncology pipeline; influencing development strategies and advancing the BMS late clinical oncology pipeline.